Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

12 hrs ago | InvestorIdeas.com

Turnaround Stories Lead Reni Benjamin's Biotech Front-Runners

July 11, 2014 The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall.

Comment?

Related Topix: Biotech, Science / Technology, Healthcare Industry, Startups, Gilead Sciences, CGI Pharmaceuticals, Merck

17 hrs ago | Dissident Voice

The Myths of Big Corporate Capitalism

Large corporate capitalism is a breed apart from smaller scale capitalism. The former can often avoid marketplace verdicts through corporate welfare, strip owner-shareholders of power over the top company bosses and offload the cost of their pollution, tax escapes and other "externalities" onto the backs of innocent people.

Comment?

Related Topix: Apple, Startups, iPhone, Biotech, Medicine, Healthcare Industry, Hepatitis, Health, US News, Liberal Political News

21 hrs ago | SiliconValley.com

Biz Break: Yahoo, Salesforce and Microsoft go shopping for startups

Today: Yahoo picks up an Israeli video startup, Salesforce agrees to buy Palo Alto big-data startup RelateIQ for $390 million, and Microsoft scoops up a San Jose company.

Comment?

Related Topix: Salesforce, Biotech, Medicine, Healthcare Industry, Celebrities, Katie Couric, Marketing

23 hrs ago | Investor's Business Daily

Stocks Mixed In Low-Volume Session; Facebook Firms Up

The Nasdaq added 0.1% while the Dow Jones industrial average and S&P 500 each slipped 0.1%.

Comment?

Related Topix: Macquarie Infrastructure Company LLC, Energy, Financial Markets, Biotech, Medicine, Healthcare Industry

Yesterday | Reuters

Senators ask Gilead to explain cost of Sovaldi hepatitis drug

Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough new treatment for hepatitis C, citing the expense to federal healthcare programs.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health, US News, US Senate, Ron Wyden, Democrat, US Politics, Startups, Gilead Sciences

Yesterday | Forbes.com

How Gilead Sciences Can Deliver A Double: Part Two

Last month, Eugene Groysman made the case that Gilead Sciences can double its stock price because of high demand for its new Hepatitis-C drug, Sovaldi, even though it costs $84,000 per treatment.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Financial Markets, Business News

Thu Jul 10, 2014

PhysOrg Weblog

EU nations join forces against 'exorbitant' hepatitis C drug: France

France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical cost.

Comment?

Related Topix: Hepatitis, Medicine, Biotech, Healthcare Industry, Social Security, Personal Finance

Seeking Alpha

A Pre-Earnings Update On Gilead

Background : Gilead Sciences may remain substantially undervalued relative to the market despite its tremendous stock price appreciation recently and over many years.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, CGI Pharmaceuticals, Genetics, Bristol Myers Squibb

Seeking Alpha

Gilead Sciences: Cause For Concern?

Gilead is a cheap stock by any sort of fundamental earnings evaluation. According to Yahoo Finance , analysts expect the company to earn $6.35 per share in 2014 and $7.92 per share in 2015.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Health Insurance

Barron's

Regeneron Picked a Heck of a Day to Announce Good News

With stocks selling off and biotech giants like Gilead Sciences and Biogen Idec falling, Regeneron picked a heck of a day to deliver good news.

Comment?

Related Topix: Biotech, Medicine, Regeneron Pharmaceuticals, Healthcare Industry, Financial Markets, Science / Technology, Biogen Idec

Seeking Alpha

Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On

Cramer consulted the technical analysis of Bob Lang to see what the charts are saying about the "Four Horsemen of Biotech": Celgene , Regeneron , Biogen Idec and Gilead .

Comment?

Related Topix: Biotech, Celgene, Medicine, Regeneron Pharmaceuticals, Healthcare Industry, Financial Markets, Williams Companies, Energy, Oil & Gas

Wed Jul 09, 2014

Forbes.com

Medical Breakthroughs And Credit Markets

Since introduction of its new breakthrough drug Sovaldi, which comes close to "curing" Hepatitis C, Gilead has been under intense public scrutiny because the three-month course of therapy "is too expensive."

Comment?

Related Topix: Hepatitis, Medicine, Biotech, Healthcare Industry, Home, Mortgage, Personal Finance

Forbes.com

Gilead Sciences Moves Up In Market Cap Rank, Passing PepsiCo

Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Comment?

Related Topix: Beverages, PepsiCo, Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, CGI Pharmaceuticals, Financial Markets

BioSpace

FDA Chides Gilead Sciences, Inc. Over A Paid Search Link

Last month, the FDA took a much-anticipated step by issuing guidelines for drug makers that want to use social media, including examples of how to run paid search links on Google.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Google, Emerging Technology, Search Engines, Hepatitis, Health

Seeking Alpha

UnitedHealth Group: A Stock For Dividend Lovers

UnitedHealth Group Incorporated is a diversified health and well-being company dedicated to help people live healthier lives and making health care more effective.

Comment?

Related Topix: Beverages, United Group, Healthcare Law, Law, Biotech, Medicine, Healthcare Industry

Tue Jul 08, 2014

The Washington Post

Temasek Invests in Health-Care, Consumer Firms to Tap New Growth

Temasek Holdings Pte is increasing investments in consumer, technology and health-care companies as Singapore's state-investment firm becomes less reliant on financial assets.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Business News

Pharma Marketing Blog

Has Gilead's Director of Regulatory Affairs Been Hiding Under a...

At the end of June, the FDA sent a Notice of Violation letter to Naumann Chaudry, Director, Regulatory Affairs Advertising and Promotion at Gilead Sciences, citing a sponsored link on Google for VIREAD .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Viread, Tenofovir (generic), Startups, AdMob, Hepatitis, Health

Mon Jul 07, 2014

Investor's Business Daily

Japan approves BMY regimen

The nod was expected but important since Japan has a high rate of infection. This puts Bristol-Myers' Daklinza and Sunvepra regimen ahead of the HCV market leader, Gilead Sciences' Sovaldi, which has not yet been approved in Japan, although it's following close behind.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry

Seeking Alpha

Gilead Sciences Has A Realistic Path To $100

Gilead does an excellent job of maintaining ownership over its active drug ingredients, and this creates cash cows that add significant contributions to cash flow per share figures.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

CNN

$1,000 a pill drug is an outrage

Activists protest drug maker Gilead Sciences to denounce the price of hepatitis C drug Sovaldi in April in Montpellier, France.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, France, World News, Health Insurance, Health, Centers for Disease Control and Prevention, Epidemic, Natural Disasters, Opinion

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••